We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Read MoreHide Full Article
Key Takeaways
Novocure found unauthorized access exposing internal IDs tied to more than 1,400 U.S. patient records.
NVCR shares rose 3.2% since the Sep. 1 disclosure and have risen 38.8% YTD.
NVCR says devices were not accessed, systems stayed functional and no material financial impact is expected.
Novocure Limited (NVCR - Free Report) recently disclosed that it identified unauthorized access to certain information systems through a subsidiary in mid-August 2026. Following detection, the company activated its cybersecurity response plan, implemented containment measures and launched an internal investigation with support from independent cybersecurity forensic experts.
Based on the investigation so far, the exposed information includes internal patient ID numbers associated with more than 1,400 U.S. patient records. These IDs are used internally and were not accompanied by patient names or other identifying information.
Data relating to fewer than 50 other patients in the western U.S. included additional identifying information. The incident also exposed general contact information for healthcare providers and Novocure employees, including job titles and phone numbers. The company said that its medical treatment devices were not accessed and that its systems remained fully functional.
NVCR Stock Trend Following the News
Shares of Novocure have gained 3.2% since the announcement on Sep. 1. Year to date, shares of the company have rallied 38.8%, outperforming the industry's 10.2% growth and the S&P 500’s 12.1% return.
The cybersecurity incident adds to growing concerns around data security across the healthcare and medical technology industry. Novocure said that its ability to operate has not been compromised and does not believe the incident will have a material or likely material impact on its financial condition. Transparent communication and timely regulatory notifications may further support trust among patients, healthcare providers, employees and investors.
NVCR currently has a market capitalization of $2.09 billion.
Image Source: Zacks Investment Research
Cybersecurity Incidents Across Medtech Industry
Novocure’s disclosure comes amid a series of cybersecurity incidents affecting major healthcare and medtech companies in 2026. Boston Scientific experienced a cybersecurity incident in August that disrupted access to certain systems and business applications, affecting aspects of order processing and shipping. McKesson disclosed a data breach involving unauthorized access to third-party applications, with the ShinyHunters hacking group claiming responsibility and alleging the theft of data from its Oncology & Multispecialty and Medical-Surgical business units.
Abbott Laboratories reported two separate cyber incidents involving unauthorized access to certain internal systems in its Cancer Diagnostics business and its LabCentral portal; the company said that the incident involved a vishing attack and did not affect its products, manufacturing or patient services. West Pharmaceutical Services faced a cyberattack in May that involved data exfiltration and encryption of certain systems, temporarily disrupting portions of its operations.
Medtronic reported unauthorized access to certain corporate IT systems, while Stryker experienced a cyberattack that disrupted its Microsoft environment and temporarily affected manufacturing, ordering and shipping activities. However, neither of the companies’ products nor patient care was compromised. During 2026, Intuitive Surgical, iRhythm and AdaptHealth also faced cybersecurity incidents, unauthorized access or data-exposure incidents without affecting medical-device functionality.
Novocure’s latest disclosure highlights the increasing importance of cybersecurity and data protection for healthcare companies. The company continues to evaluate applicable legal and regulatory notification requirements and expects to notify affected individuals as required.
Other News
In June, NovoCure’s portable medical device, Option Pax, received the CE (Conformité Européenne) mark for treating adult patients with locally advanced pancreatic cancer of exocrine origin. The non-invasive device is approved in Europe in combination with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. The guideline recommendations account for the local differences, as use of gemcitabine and nab-paclitaxel may vary by market.
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Novocure Reports Patient Data Exposure in Cybersecurity Incident
Key Takeaways
Novocure Limited (NVCR - Free Report) recently disclosed that it identified unauthorized access to certain information systems through a subsidiary in mid-August 2026. Following detection, the company activated its cybersecurity response plan, implemented containment measures and launched an internal investigation with support from independent cybersecurity forensic experts.
Based on the investigation so far, the exposed information includes internal patient ID numbers associated with more than 1,400 U.S. patient records. These IDs are used internally and were not accompanied by patient names or other identifying information.
Data relating to fewer than 50 other patients in the western U.S. included additional identifying information. The incident also exposed general contact information for healthcare providers and Novocure employees, including job titles and phone numbers. The company said that its medical treatment devices were not accessed and that its systems remained fully functional.
NVCR Stock Trend Following the News
Shares of Novocure have gained 3.2% since the announcement on Sep. 1. Year to date, shares of the company have rallied 38.8%, outperforming the industry's 10.2% growth and the S&P 500’s 12.1% return.
The cybersecurity incident adds to growing concerns around data security across the healthcare and medical technology industry. Novocure said that its ability to operate has not been compromised and does not believe the incident will have a material or likely material impact on its financial condition. Transparent communication and timely regulatory notifications may further support trust among patients, healthcare providers, employees and investors.
NVCR currently has a market capitalization of $2.09 billion.
Image Source: Zacks Investment Research
Cybersecurity Incidents Across Medtech Industry
Novocure’s disclosure comes amid a series of cybersecurity incidents affecting major healthcare and medtech companies in 2026. Boston Scientific experienced a cybersecurity incident in August that disrupted access to certain systems and business applications, affecting aspects of order processing and shipping. McKesson disclosed a data breach involving unauthorized access to third-party applications, with the ShinyHunters hacking group claiming responsibility and alleging the theft of data from its Oncology & Multispecialty and Medical-Surgical business units.
Abbott Laboratories reported two separate cyber incidents involving unauthorized access to certain internal systems in its Cancer Diagnostics business and its LabCentral portal; the company said that the incident involved a vishing attack and did not affect its products, manufacturing or patient services. West Pharmaceutical Services faced a cyberattack in May that involved data exfiltration and encryption of certain systems, temporarily disrupting portions of its operations.
Medtronic reported unauthorized access to certain corporate IT systems, while Stryker experienced a cyberattack that disrupted its Microsoft environment and temporarily affected manufacturing, ordering and shipping activities. However, neither of the companies’ products nor patient care was compromised. During 2026, Intuitive Surgical, iRhythm and AdaptHealth also faced cybersecurity incidents, unauthorized access or data-exposure incidents without affecting medical-device functionality.
Novocure’s latest disclosure highlights the increasing importance of cybersecurity and data protection for healthcare companies. The company continues to evaluate applicable legal and regulatory notification requirements and expects to notify affected individuals as required.
Other News
In June, NovoCure’s portable medical device, Option Pax, received the CE (Conformité Européenne) mark for treating adult patients with locally advanced pancreatic cancer of exocrine origin. The non-invasive device is approved in Europe in combination with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations. The guideline recommendations account for the local differences, as use of gemcitabine and nab-paclitaxel may vary by market.
NovoCure Limited Price
NovoCure Limited price | NovoCure Limited Quote
NVCR’s Zacks Rank & Other Key Picks
Currently, NVCR carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and West Pharmaceutical (WST - Free Report) .
Veracyte, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.